CentoCloud® - One-Stop-Solution for laboratories

For diagnostic NGS panels, clinical bioinformatics & medical interpretation

Quality medical reports demand efficient access to diagnostic bioinformatics, variant annotation, and clinical interpretation.

  1. Pharma

What is CentoCloud®?

CentoCloud® is a service specifically designed for human genetic laboratories to support the execution of high-standard Next generation sequencing diagnostics. The fully automated bioinformatics pipeline analyzes pre-produced NGS data based on validated gene panel kits, annotated with data from our proprietary mutation database (CentoMD®).


CentoCloud® provides

  • Ready to use NGS technology
  • Easy sample collection using our proprietary filtercard CentoCard®
  • Web-based bioinformatics incl. CentoMD® annotation

When is CentoCloud® right for your lab?

If there is ...

  • A demand to outsource complex samples for NGS analysis

  • Missing diagnostic software to execute bioinformatics analysis

  • An investment barrier for your own NGS sequencer technology

  • IT hardware and server technology outdated

  • A need to implement efficient test systems with new technology

  • An increase in your diagnostic portfolio

CentoCloud® is your one-stop solution

What CentoCloud® offers

Bioinformatics pipeline development and an efficient gene panel design

Workstation setup & validation - if necessary accreditation and QM

Seamless LIMS integration

Technical & medical consulting - training and mentoring in all relevant questions

Direct access to CentoMD®, the world‘s largest and best‑curated databank of rare genetic disorders

The solution

CentoCloud® panel options (ready-to-use)

  CentoCloud® Mendeliome CentoCloud® Oncology
Indication For multiple hereditary diseases, especially treatable diseases, early onset childhood disorders (epilepsies, mental retardation), cardiac disorders, neurodegenerative diseases, skeletal abnormalities, skin and sensory diseases For all relevant hereditary tumor predisposition syndromes including breast cancer, GI tumors, Li‑Fraumeni syndrome, MEN1, MEN2, paragangliomas etc.
Genes
  • 2,397 genes, 13Mb target region (v1)
  • CNV analysis available
  • 56 genes, 0.5Mb target region (v1)
  • CNV analysis available
Coverage >98% targeted bases at >20x covered
  • >99% targeted bases at >20x covered
  • 100% coverage of core genes BRCA1, BRCA2, TP53
Conditions Unique gene composition addressing the most relevant indications for genetic testing Hereditary cancer syndromes
Patient group Children and adults with a suspected genetic disorder Tumor patients and relatives with increased risk of tumor
TAT

Processing: <5 days (2 days for prenatal option)
Medical Reporting: <2days

Processing: <5 days
Medical Reporting: <2days

Under development:

CentoCloud™ Screen (screens parents-to-be for carriership in severe recessive diseases)
CentoCloud™ Health (predictive testing to uncover genetic predisposition for treatable disorders)

For other validated panel designs and workflows from our test portfolio, please see our test catalogue.


Downloads for CentoCloud®

CentoCloud® significantly reduces costs